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 INTRODUCTION1,2,3,4
Living things are those, which make the entire world productive and interesting. The
absence  of  the  living  things  proves  the  world  futile.  Among  the  living  things  such  as
microorganism, plants, animals and human, it is the human being, which predominates, and
there by leads and of course rules over the other.
As the days moves on rapidly it  is a noted fact  that  the life style,  culture and the
environment of the mankind has changed tremendously. In this rapidly changing world the
emergence  of  various  life  threatening illness,  diseases  and other  serious  syndromes  have
become vary common and also a part of life. In order to eradicate the emergence of the new
diseases and also to get rid out of various existing diseases. The inventions of newer agents or
newer molecules become the concern.
In the act of invention of newer agents and molecules there are various aspects to the
considered such as easy availability, affordability, low manufacturing cost, high efficacy and
with minimal side effects.
Considering the various  above said factors  the  medicinal  chemists  throughout  the
world  are  seriously  as  well  as  sincerely  involved  in  the  newer  drug  synthesis  and  it
determination to enable as well as to enhance the well being of the mankind.
The  hundreds  or  thousands  of  new  organic  chemicals  are  prepared  annually
throughout the world and many of them entered into pharmacological screens to determine
whether  they have  useful  biological  activity.  This  process  of  random screening has  been
considered inefficient but it has resulted in the identification of new drugs and it have been
determined quantitatively.
ANALYTICAL CHEMISTRY1,4,7
Analytical chemistry is a scientific discipline used to study the chemical composition,
structure and behaviour of matter. The purpose of this is to gather and interpret chemical
information that will be of value to society in a wide range of contexts. 
Any chemical analysis can be broken down into a number of stages that include a
consideration  of  the  purpose  of  the  analysis,  the  quality  of  the  results  required  and  the
individual steps in the overall analytical procedure. Analytical procedure summarized by the
following steps.
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1. Definition of the problem.
2. Choice of technique and method.
3. Sampling 
4. Sample pretreatment or conditioning
5. Qualitative analysis
6. Quantitative analysis
7. Preparation of report or certificate of analysis
8. Review of the original problem.
QUANTITATIVE ANALYSIS:
It  is  the determination of the absolute or relative amounts of elements,  species  or
compounds present in sample.
QUALITATIVE ANALYSIS:
It is the identification of elements, species and/or compounds present in a sample.
ANALYTICAL TECHNIQUE:
There  are  numerous  chemical  or  physico-chemical  processes  that  can  be  used  to
provide  analytical  information.  The processes  are  related  to  a  wide range  of  atomic and
molecular  properties  and phenomena that  enable  elements and compounds to be detected
and/or quantitatively measured under controlled conditions. Instrumental techniques are used
for much analysis and constitute the discipline of instrumental analysis. Atomic or molecular
spectrometry and chromatography, which together comprise the largest and most widely used
groups of techniques, can be further subdivided according to their physico chemical basis.
ANALYTICAL METHODS
Analytical methods are a detailed set of instructions for a particular analysis using a
specified  technique.  Many standard  analytical  methods have  been  published as  papers  in
analytical journals and other scientific literature, and in textbook form often, laboratory will
develop their own "in-house methods" or adapt existing ones for specific purposes. 
Method  development  forms  a  significant  part  of  the  work  of  most  analytical
laboratories  and  method  validation  and  periodic  revalidation  is  a  necessity.  Analytical
methods must be shown to give reliable data, free from bias and suitable for the intended use.
Most methods are multi step procedures, and the process of validation generally involves a
stepwise approach in which optimized experimental parameters are tested for robustness that
is sensitivity to variations in the conditions and sources of errors investigated. 
The instrument is only one component of the total analysis. Often it is necessary to
use several instrumental techniques to obtain the information required to solve an analytical
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problem.  Analytical  chemists  to  save  time,  to  avoid  chemical  separation  or  to  obtain
increased accuracy, may use instrumental method. The time saving feature can be realized in
routine analysis, or where a considerable number of determinations are to be made. Most
instrumental  techniques  fit  into  one  of  the  three  principal  areas:  Spectroscopy,
Electrochemistry and Chromatography.
PRINCIPLE TYPES OF CHEMICAL INSTRUMENTATION:
A. Spectrometric techniques:
 Ultra violet and Visible Spectrophotometry
 Fluorescence and Phosphorescence Spectrophotometry
 Atomic Spectrometry (Emission and Absorption)
 Infrared Spectrophotometry
 Raman Spectroscopy
 X-ray Spectroscopy
 Radiochemical techniques including activation analysis
 Nuclear Magnetic Resonance Spectroscopy
 Electron Spin Resonance Spectroscopy
B. Chromatographic techniques
 Gas Chromatography
 High Performance Liquid Chromatography
 Thin layer Chromatography
C. Electrochemical techniques
 Potentiometry
 Voltametry
 Stripping Techniques
 Amperometric Techniques.
 Colorimetry
 Electrogravimetry
 Conductance Techniques
D. Miscellaneous Techniques
 Thermal Analysis
 Mass Spectrometry
 Kinetic Techniques
E. Hyphenated Techniques:
 GC-MS (Gas Chromatography - Mass Spectrometry)
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 ICP-MS (Inductivity Coupled Plasma Mass Spectrometry)
 GC-IR (Gas Chromatography - Infrared Spectroscopy)
 MS-MS (Mass Spectrometry - Mass Spectrometry)
ANALYTICAL DEVELOPMENT:4,7,8,9,10
Devising  accurate  assay  procedures  for  each  ingredient  of  complex  dosage
formulations containing several therapeutically and chemically compatible drugs with very
similar  chemical  nature  is  a  monumental  undertaking.  Separation,  identification  and
estimation of each ingredient in such complex formulations is a challenging task.
Not only are the multiple active constituents present but also they are usually there in
widely divergent concentration depending upon their relative potency and therapeutic need of
the patient. 
The presence of excipients, additives and decomposition products further complicates
the analysis. Therefore analytical development is done for new drugs where no compendial
methods are available. Or, alternate method development for existing (Non Pharmacopoeial)
products to reduce cost and time of analysis.
Method development is done for:
1. New products.
2. Existing products
Methods are  developed  for  new products  when no official  methods  are  available.
Alternate methods for existing (Non- Pharmacopoeial) products are developed to reduce the
cost  and  time  for  better  precision  and  ruggedness.  Trial  runs  are  conducted,  method  is
optimized and validated.
When  alternate  method  proposed  is  intended  to  replace  the  existing  procedure
comparative laboratory data including merit/demerits are made available.
Selection of analytical method:
First stage in the selection or development of method is to establish what is being
measured and how accurately it should be measured.
The following analytical  techniques are usually employed  for estimations different
components in formulations:
1. Titrimetric and Gravimetric.
2. Ultraviolet and visible Spectrophotometry.
3. Thin layer chromatography.
4. High Performance Liquid Chromatography (HPLC)
5. Gas Chromatography (GC)
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6. Atomic absorption Spectrometry (AAS)
7. Infrared absorption Spectrophotometry.
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6MAJOR STEPS IN SOLVING AN ANALYTICAL PROBLEM
Describe sample,
Desired information
& Appropriate methods
Define problem
Select appropriate 
method (s)
Analytical 
techniques
Obtain and store 
sample
Pretreat sample
Performed required 
measurements 
Compare results with 
standards
Apply necessary 
statistical
Present results in form 
understandable to 
analyst
Present results to 
customer
Refined data into 
information
Information is 
transformed into 
useful knowledge
It may be 
necessary to 
modify some 
procedures and 
repeat analysis to 
obtain desired 
information
Analyst
METHOD DEVELOPMENT:
For the development of an analytical method various steps are followed which are
considered essential for establishing the required documental evidence to prove that the said
method is  ideal  and reproducible.  The various steps followed in developing an analytical
method is shown in following table:
STEPS OF METHOD DEVELOPMENT:
Documentation starts at the very beginning of the development process, a system for
full documentation of the development studies must be established. All data relating to these
studies must be established. All data relating to these studies must be recorded in laboratory
notebook or an electronic database.
1. Analyte standard characterization:
 All  known information  about  the  analyte  and  its  structure  is  collected  i.e.
physical  and  chemical  properties,  toxicity,  purity,  hygroscopic  nature,
solubility and stability.
 The standard  analyte  (100% purity)  is  obtained.  Necessary  arrangement  is
made for the proper storage (refrigerator, desiccators, freezer)
 When  multiple  components  are  to  be  analyzed  in  the  sample  matrix,  the
number  of  components  is  noted,  data  is  assembled  and  the  availability  of
standards for each one is determined.
 Special attention has to be paid when samples are limited (small volume or
mass) or an analyte is present at trace levels, it is noted.
 Only those methods (MS, GC, HPLC etc.) that are compatible with sample
stability are considered.
2. Method Requirements:
The goals or requirements of the analytical method that need to be developed
are considered and the analytical figures of merit are defined. The required detection
limits, selectively, linearity, range, accuracy and precision are defined.
3. Literature search and prior methodology:
The literature for all types of information related to the analyte is surveyed.
For  synthesis,  physical  and  chemical  properties,  solubility  and  relevant  analytical
methods.  Books,  periodicals,  chemical  manufactures  and  regulatory  agency
compendia such as USP/NF, AOAC and ASTM publications are reviewed. Chemical
Abstracts Service (CAS) automated computerized literature searches are convenient.
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4. Choosing a method:
 Adaptation  is  more  efficient  than  "reinventing  the  wheel".  If  any  of  the
reported methods from the literature are adaptable to the current  laboratory
setting and future needs, it is determined.
 Using the information in the literatures and prints, methodology is adapted.
The methods are modified wherever necessary. Sometimes it is necessary to
acquire additional instrumentation to reproduce, modify, improve or validate
existing methods for in-house analytes and samples.
 If there are no prior methods for the analyte in the literature, from analogy, the
compounds  that  are  similar  in  structure  and  chemical  properties  are
investigated and are worked out. There is usually one compound for which
analytical method already exist that is similar to the analyte of interest.
5. Instrumental setup and initial studies:
 The  required  instrumentation  is  set  up.  Installation,  operational  and
performance  qualification  of  instrumentation  using  laboratory  standard
operating procedures (SOP's) are verified.
 Always  new  consumables  (e.g.  Solvents,  filters  and  gases)  are  used,  for
example, method development is never started, on a HPLC column that has
been used earlier.
 The  analyte  standard  in  a  suitable  injection  /  introduction  solution  and  in
known concentrations and solvents are prepared. It is important to start with
an authentic, known standard rather than with a complex sample matrix. If the
sample is extremely close to the standard (e.g. bulk drug), then it is possible to
start work with the actual sample.
 The  analysis  is  done  using  analytical  conditions  described  in  the  existing
literature.
 Feasibility of method with regard to the analytical figures of merit obtained is
evaluated.
6. Optimization:
During optimization one parameter is changed at a time, and set of conditions
are isolated, rather than using a trial and error approach. Work has been done form an
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organized methodical plan, and every step is documented (in a lab notebook) in case
of dead ends.
7. Documentation of analytical figures of merit:
The originally  determined analytical  figures  of  merit  Limit  of  Quantitation
(LOQ),  Limit  of  Detection  (LOD),  linearity,  time  per  analysis,  cost,  sample
preparation etc are documented.
8. Evaluation of method development with actual samples:
The sample solution should lead to unequivocal, absolute identification of the
analyte peak of interest from all other matrix components.
9. Determination  of  percent  recovery  of  actual  sample  and  demonstration  of
quantitative sample analysis:
Percent recovery of spiked, authentic standard analyte into a sample matrix
that  is  shown  to  contain  no  analyte  is  determined.  Reproducibility  of  recovery
(average +/- standard deviation) from sample to sample and whether  recovery has
been optimized has been shown. It is not necessary to obtain 100% recovery as long
as the results are reproducible and known with a high degree of certainty.
The  validity  of  an  analytical  method  can  be  verified  only  by  laboratory  studies.
Therefore documentation of the successful completion of such studies is a basic requirement
for determining whether a method is suitable for its intended applications.
Brief description of the various analytical methods:
B. SPECTROSCOPY:
In  Spectrometric  methods,  the  sample  solution  absorbs  Electromagnetic  Radiation
from an appropriate source, and the amount absorbed is related to the concentration of the
analyte in solution.
UV AND VISIBLE SPECTROSCOPY:
Ultraviolet  and  visible  radiation  is  involved  with  electronic  excitation.
Spectroscopically,  UV and visible radiation operates with wavelength between 20-800nm.
The UV and visible spectroscopy is based on the principle of beer-lamberts law relating to
intensity  of  light  with  thickness  and  concentration  of  medium.  The  UV  and  visible
spectroscopy  is  concerned  with  the  quantitative  analysis  and  structural  elucidation.  The
instrumentation  of  UV  and  visible  spectrophotometer  consists  of  radiation  source;
monochromators,  sample  cells,  detectors,  recording  systems,  powering  supply.  They  are
Double  beam and  Single  beam spectrophotometers.  Ultraviolet  and  visible  spectrometric
method is suitable when no interference is observed in the mixture.
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CHROMATOGRAPHY
It is the process of separating the components of mixtures (solutes) that are distributed
between a stationary phase and a flowing mobile phase according to the rate at which they are
transported through the stationary phase.
Chromatographic  technique  can  be  classified  according  to  whether  the  separation
takes place on a planar surface or in a column. They can be further subdivided into gas and
liquid chromatography, and by physical form, solid or liquid of the stationary phase and the
nature of the interactions of solutes with it known as sorption mechanism.
HPLC -- HIGH PRESSURE (PERFORMANCE) LIQUID CHROMATOGRAPHY 
High  Performance  Liquid  Chromatography  (HPLC)  is  a  chemistry  based  tool  for
quantifying and analyzing mixtures of chemical compounds. It's used to find the amount of a
chemical  compound  within  a  mixture  of  other  chemicals.  High  Performance  Liquid
Chromatography (HPLC) is an analytical technique for the separation and determination of
organic  and inorganic  solutes  in any samples  especially  biological,  pharmaceutical,  food,
environmental, industrial, etc. In a liquid chromatographic process a liquid permeates through
a  porous  solid  stationary  phase  and  elutes  the  solutes  into  a  flow-through  detector.  The
stationary phase is usually in the form of small-diameter (5-10 mm) uniform particles, packed
into a cylindrical column. The typical column is constructed from a rigid material (such as
stainless steel or plastic) and is generally 5-30 cm long and the internal diameter is in the
range of 1-9 mm
1. Increase resolution of liquid chromatography by... 
 Use very small  particles to get  the large possible surface area   3 - 20 µ
diameter
 High pressure (up to 400 atmospheres) needed to get acceptable flow rates 
requires  very  strong  particles  to  resist  bed  compression  and  crushing  of
particles.
 Tens of thousands of "plates" per meter of column length provides excellent
resolution
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1 Used  in  most  of  the  normal  modes  discussed  above  although  reversed  phase is
probably the most common type of HPLC 
2 Advantages: very high resolution (replaces Paper chromatography / Electrophoresis in
most applications) and short run times. 
REVERSED PHASE CHROMATOGRAPHY
1. Stationary  Phase --  Apolar  (hydrophobic)   reversed  with  respect  to  cellulose
chromatography 
 Hydrocarbon chains --  bound to  an  inert  matrix;  hydrophobicity  varied by
changing the hydrocarbon chain length
 Aromatic groups 
1 Mobile Phase -- depends upon hydrophobicity of stationary phase. Commonly use a
more  polar  organic  solvent:  Acetonitrile,  DMSO,  EtOH,  Ethylene  glycol,  Propanol,  or
mixtures of these with H2O. Also may use gradients. 
CHROMATOGRAPHY SCALE: 
• Analytical - Just Data [High Sensitivity] 
• Semi-Preparative - Data and a small amount of purified analyte (gram) 
• Preparative - Larger quantities of purified analytes (Kilograms) [High Capacity]
TYPES OF CHROMATOGRAPHY
There are three main types of chromatography, categorized by the mobile phase type: 
• Gas (GC) 
• Liquid (LC) 
• Supercritical fluid (SFC)
.MOBILE PHASE:
• Type of modifier (MeoH, Acetonitrile)
• Solvent Strength
• PH
• Type of buffer(Phosphate, acetate)
• Ionic strength (salts, Buffer concentration)
• Ion-Pairing Reagents (alkylamines, -sulfonates)
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CHIRAL STATIONARY PHASES 
• Ligand exchange 
• p-Donor p-acceptor (Pirkle) 
• Chiral Host-guest (cyclodextrin) 
• Immobilized proteins 
• Immobilized polysaccharides 
This is  a highly specific  mode of  chromatography in which molecular  recognition
process takes place between the agents bonded to the stationary phase and the solutes. The
principle  of  lock-key  recognition  similar  to  enzymes  takes  place.  In  size  exclusion
chromatography molecules are separated based on their molecular size in a sieving effect.
The bigger molecules (higher molecular weight) elute earlier. 
The  system  is  calibrated  using  standards  of  known  molecular  weights  and  the
unknown's molecular size distribution is determined from the calibration curve.  Retention
times are related to the log MW (logarithm of molecular weight). There are many variables to
consider  when  selecting  the  mode  of  chromatography  to  work  with.  Since  most  of  the
applications  use  Reversed  Phase,  all  these  variables  are  taken  into  consideration  during
method development for this mode of HPLC. 
HPLC COLUMNS:
1.  The most efficient columns produce the sharpest peaks, which gives better separation by
minimizing band spreading
2. A tight narrow sample “band” is produced when a column’s stationary phase is uniformly
packed (mechanical)
3.The packing material adds “chemical” band spreading (tailing, pore depth etc.).
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Separation can be achieved by controlling and manipulating these interactions, which effect the
relative retention times of the various sample components. 
DATA SYSTEM - A means of controlling the system components and storing, processing
and displaying data 
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PUMPS:
A high pressure pump is required to force the mobile phase through the column at
typical flow rates of 0.1-2 ml/min. The sample to be separated is introduced into the mobile
phase by injection device, manual or automatic, prior to the column.
DETECTORS:
Instrument in the chromatographic system which senses the presence of a compound
passing through, and provides an electronic signal  to a recorder or computer data station.
Output is usually peaks, that is, the chromatogram.
TYPES OF DETECTORS: 
• UV – Ultraviolet light 
o Lamp 
o Grating/Lens - Wave length 
o Flow Cell 
o Photo Diode - Differential Light Output
• RI – Refractive Index 
o Universal analyte detector 
o Solvent must remain the same throughout separation 
o VERY temperature sensitive 
o Sometimes difficult to stabilize baseline
• FD – Fluorescence 
o Excitation wavelength generates fluorescence emission at a higher wavelength
o Analytes must have fluorophore group 
 Can react analyte with fluorophore reagent 
o Very sensitive and selective 
o More difficult methods transfer 
o Results very dependent upon separation conditions
• MS – Mass Spectrometer 
o Mass to charge ratio (m/z) 
o Allows specific compound ID 
o Several types of ionization techniques 
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 Electrospray,  Atmospheric  pressure  chemical  ionization,  electron
impact 
The detector usually contains low volume cell through which the mobile phase passes 
carrying the sample components. Choosing a Detector.  
  
 Criteria RI UV/VIS Fluor. MS
Response Universal Selective Selective Selective
Sensitivity 4 microgram 5 nanogram 3 picogram 1 picogram 
Linear Range 10 10 10 10
Flow Sensitive Yes No No Yes
Temp. Sensitive Yes No No No
Seven Basic Considerations in Choosing HPLC Operating Parameters:
1. Solubility - Hexane, Chloroform, Methanol, Water (buffer pH), other 
2. Molecular Weight - Would GPC be useful in either the analysis or sample prep? 
3. Functional Groups - Any ionizable groups? Acidic, Basic, or Neutral? 
4. Sample  Matrix  -  What  amounts  are  expected  in  matrix  for  either  analytical  or
preparative isolation? 
5. Levels  in  Matrix  -  What  amounts  are  expected  in  matrix  for  either  analytical  or
preparative isolation? 
6. Detectability - Any chromophores or fluorophores? Consider Redox or derivatization.
Together with point #5, an appropriate detector is chosen. 
7. How  Do  Species  Differ  -  An  important  clue  to  manipulate  selectivity  in  the
separation, especially if compounds are similar in their structure. 
VALIDATION:15,16
Validation is an approach to form a basis for written procedures for production and
process  control  which  are  designed  to  assure  that  the  drug  products  have  the  identity,
strength, quality and purity they purport or are represented possess. 
Validation is defined as follows by different agencies:
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FOOD AND DRUG ADMINSTRATION (FDA):
Establishing documentation evidence, which provides a high degree of assurance that
specific process, will consistently produce a product meeting its predetermined specification
and quality attributes.
WORLD HEALTH ORGANISATION (WHO):
Action  of  providing  that  any  procedure,  process,  equipment,  material,  activity  or
system actually leads to the expected results.
EUROPEAN COMMITTEE (EC):
Action of providing in accordance with the principles of good manufacturing practice,
that  any procedure,  processes,  equipment material,  activity or system actually lead to the
expected results.
In  brief validation is a key process for effective Quality Assurance.  "Validation is
establishing documental evidence which provides a high degree of assurance that a specific
process  or  equipment  will  consistently  produce  a  product  meeting  its  predetermined
specification and quality attributes".
OBJECTIVE OF VALIDATION:
The  primary objective  of  validation is  to  form a  basis  for  written  procedures  for
production and process control which are designed to assure that the drug products have the
identity, strength, quality and purity they purport or are represented to possess.
 Quality, safety and efficacy must be designed and built into the product.
 Each step of the manufacturing process must be controlled to maximize the
probability  that  the  finished  product  meets  all  quality  and  design
specifications.
BENEFIT:
 QUALITY: Customer-patient satisfaction. It has been built into the product.
 UNDERSTANDING  EQUIPMENT,  SYSTEMS,  PROCESSES:  Process
improvement,  technology  transfer,  related  product  validation,  rapid  failure
investigations, increased employee awareness.
 COST REDUCTION:
• Increased  efficiency,  shortening  lead-time  resulting  in  lower
inventories.
• Fewer rejects and reworks.
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• Longer  equipment  life  by  operating  the  equipment  as  per
manufacturer's  specifications  and  the  establishing  of  cost  effective
preventive maintenacne schedules.
• Possible  reduced  testing  of  raw  materials  bulk  formulations  and
finished products
 REGULATORY:
• Successful inspections
• Approved products
• Ability to export.
PHASES OF VALIDATION:
• Design Qualification (DQ): Documented verification of the design of equipment and
manufacturing facilities.
• Installation  Qualification  (IQ): Documented  verification  of  equipment  or  system
design and adherence to manufacturer's recommendations.
• Operational  Qualification (PQ): Documented verification that equipment or system
performance in the target operating range.
• Process performance Qualification (PQ): Documented verification that equipment or
systems operate as expected under routine production conditions.  The operation is
reproducible, reliable and in a state of control.
• Process / Product Validation: Validation is establishing documented evidence, which
provides a high degree of assurance that a specific process will consistently produce a
product meeting its pre-determined specifications and quality attributes.
TYPES OF VALIDATION:
 PROSPECTIVE VALIDATION: This is performed for all new equipment,
products and processes. It is a proactive approach of documenting the design,
specifications and performance before the system is operational. This is the
most defendable type of validation.
 CONCURRENT VALIDATION: This is performed in two instances i.e. for
existing  equipment;  verification  of  proper  installation  along  with  specific
operational tests is done. In case of an existing, infrequently made product,
data is gathered from at least three successful trials.
 RETROSPECTIVE  VALIDATION:  This  is  establishing  documented
evidence  that  the  process  is  performed  satisfactorily  and  consistently  over
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time, based on review and analysis of historical data. The source of such data
is production and QA/QC records. The issues to be addressed here are changes
to equipment, process, specifications and other relevant changes in the past.
DATA ELEMENTS REQUIRED FOR ASSAY VALIDATION:
Most  common categories  of  assays  for  which  validation  data  should  be  required.
These categories are as follows.
CATEGORY I: - Analytical methods for quantitation of major components of bulk drug
substances  or  active  ingredients  (including  preservatives)  in  finished  pharmaceutical
products.
CATEGORY  II:  - Analytical  methods  for  determination  of  impurities  in  bulk  drug
substances or degradation compounds in finished pharmaceutical products. These methods
include quantitative assays and limit tests.
CATEGORY III:  - Analytical  methods for  determination  of  performance  characteristics
(e.g. dissolution, drug release)
CATEGORY IV: - Identification test.
For  each  assay  category,  different  analytical  information  is  needed.  Data
elements that is normally required for each of the categories of assays.
DATA ELEMENTS REQUIRED FOR VARIOUS CATEGORIES OF ASSAYS
Analytical
performance
characteristics
Assay
category I
Assay category II
Assay
category III
Assay
category IVQuantitative Limit test
Accuracy Yes Yes ¤ ¤ No
Precision Yes Yes No Yes No
Specificity Yes Yes Yes ¤ Yes
Detection
limit
No No Yes ¤ No
Quanititation
limit
No No No ¤ No
Linearity Yes Yes No ¤ No
Range Yes Yes ¤ ¤ No
¤  may be required, depending on the nature of the specific test
ANALYTICAL METHOD VALIDATION:
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Analytical monitoring of a pharmaceutical product or of specific ingredients within
the product is necessary to ensure its safety efficacy throughout all phases of its shelf life.
Such  monitoring  is  in  accordance  with  the  specifications  elaborated  during  product
development. Analytical validation is the cornerstone of process validation without a proven
measurement system it is impossible to confirm whether the manufacturing process bas done
what it purports to do. All new methods developed are validated.
Steps followed for validation procedures:
1. Proposed protocols or parameters for validations are established
2. Experimental studies are conducted.
3. Analytical results are evaluated.
4. Statistical evaluation is carried out.
5. Report is prepared documenting all the results.
OBJECTIVE:
The objective of validation of an analytical procedure is to demonstrate that is suitable
for  its  intended purpose.   Validation of  analytical  methods is  the  process  by which it  is
established laboratory studies that  the performance characteristics of the method meet the
requirements for the intended analytical applications. According to ICH, typical  analytical
performance  characteristics  that  should  be  considered  in  the  validation  of  the  types  of
methods are
1. Accuracy
2. Precision
3. Specificity
4. Detection limit
5. Quantitation limit
6. Linearity
7. Range
The ICH documents give guidance on the necessity for revalidation in the following
circumstances
1. Changes in the synthesis of the drug substances.
2. Changes in the composition of the drug product, and
3. Changes in the analytical procedures.
ANALTICAL PERFORMANCE CHARACTERISTICS:
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ACCURACY:
Accuracy is the closeness of test results obtained by that method to the true value. The
accuracy of an analytical method should be established across its range.
Determination of accuracy:
In case of assay of a drug substance accuracy may be determined by application of the
analytical method to an analyte of known purity (e.g. reference standard) or by comparison of
the results of the method with those of a second well characterized method, the accuracy of
which has been stated or defined. Accuracy is calculated as the percentage of recovery by the
assay of the known added amount of analyte in the sample, or as the difference between the
mean and the accepted true value, together with confidence intervals. The ICH documents
recommended that accuracy should be assessed using a minimum of nine determinations over
a  minimum  of  three  concentration  levels,  covering  the  specified  range  (i.e.,  three
concentrations and three replicates of each concentration)
PRECISION:
Precision is the degree of agreement among individual test results when the method is
applied repeatedly to multiple samplings of a homogenous sample. Precision of an analytical
method  is  usually  expressed  as  the  standard  deviation  or  relative  standard  deviation
(coefficient of variation) of a series of measurement. Precision may be measure of either the
degree of reproducibility or repeatability of the analytical  method under normal operating
conditions.
Determination of precision:
Precision of an analytical method is determined by assaying a sufficient number of
aliquots  of  a  homogenous  sample  to  be  able  to  calculate  statistically  valid  estimates  of
standard  deviation  or  relative  standard  deviation  (coefficient  of  variation).  The  ICH
documents  recommend  that  repeatability  should  be  assessed  using  a  minimum  of  nine
determinations covering the specified range for the procedure.
SPECIFICITY:
ICH documents defines specificity as the ability to assess unequivocally the analyte in
the presence of compounds that may be expected to present, such as impurities, degradation
products and matrix components.
IDENTIFICATION TESTS:
It ensure the identify of an analyte.
PURITY TEST: -
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It ensures that all the analytical procedures performed allow an accurate statement of
the  content  of  impurities  of  an  analyte.  (e.g.  related  substances  test,  heavy  metals  limit,
Organic volatile impurity test).
ASSAY:
It  provides  an  exact  result,  which  allows  as  accurate  statement  on  the  content  or
potency of the analyte in a sample.
SPECIFICITY:
ICH documents state that when chromatographic procedures are used, representative
chromatograms should be presented to demonstrate the degree of selectivity and peaks should
be appropriately labeled. Peak purity tests (e.g. Using diode array or mass spectrometry) may
be useful to show that the analyte chromatographic peak is not attributable to more than one
component.
DETECTION LIMIT:-
Characteristic of limit tests: Lowest amount of analyte in a sample that can be detected, but
not necessarily quantities as an exact value, under the stated experimental conditions. The
detection limit is usually expressed as the concentration of analyte  (e.g. percentage parts per
million) in the sample.
Determination of detection limit:
For  instrumental  and  non-instrumental  methods  detection  limit  is  generally
determined  by  the  analysis  of  samples  with  known  concentrations  of  analyte  and  by
establishing the minimum level at which the analyte can be reliably detected. 
In case of instrumental analytical procedures that exhibit background noise, the ICH
documents describe a common approach which is to compare measured signals from samples
with  known  low  concentrations  of  analyte  with  those  of  blank  samples.  The  minimum
concentration  at  which  the  analyte  can  be  reliably  detected  is  established.  Typically
acceptable signal-to-noise ratios are 2:1 or 3:1. Whatever method is used, the detection limit
should be subsequently validated by the analysis of a suitable number of samples known to
be near, or prepared at the detection limit.
QUANTITATION LIMIT:
It is the lowest amount of analyte in a sample that can be determined with acceptable
precision  and  accuracy  under  the  stated  experimental  conditions.  Quantitation  limit  is
expressed as the concentration of analyte (e.g. Percentage parts per billion) in the sample.
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Determination of Quantitation limit:
For  instrumental  and non-instrumental  methods,  the quantitation limit  is  generally
determined  by  the  analysis  of  samples  with  known  concentration  of  analyte  and  by
establishing  the  minimum level  at  which  the  analyte  can  be  determined  with  acceptable
accuracy and precision. In case of instrumental analytical methods that exhibit background
noise,  the  ICH  documents  describe  a  common approach,  which  is  to  compare  measured
signals from samples with known low concentration of analyte with those of blank samples.
A typically acceptable signal-to noise ratio is 10:1. Whatever method is used, the quantitation
limit  should  be  subsequently  validated  by the  analysis  of  a  suitable  member  of  samples
known to be near, or prepared at, the quantitation limit.
LINEARITY AND RANGE:
Linearity of an analytical method is its ability to elicit test results that are directly or
by a well-defined mathematical transformation, proportional to the concentration of analyte
in samples within a given range. The range of an analytical method is the interval between
the upper and lower levels of analyte (including these levels). 
That  has  been  demonstrated  to  be  determined  with  a  suitable  level  of  precision,
accuracy and linearity using the method as written.  Range is normally expressed in the same
units as test results (e.g. found parts per million) obtained by the analytical method.
Determination of linearity and range:
Linearity should be established across the range of the analytical procedure. Initially
by visual examination of a plot of signals as a function of analyte concentration of content. If
linear relationship appears, test results are established by appropriate statistical methods (e.g.
by calculation of a regression line by the method of least squares)
The range of the method is validated by verifying that the analytical method provides
acceptable precision, accuracy, and linearity when applied to sample containing analyte at the
extremes of the range as well as within the range. ICH recommends that for the establishment
of linearity, a minimum of five concentrations normally be used.
RUGGEDNESS:
Degree of reproducibility of test results obtained by the analysis of the same samples
under  a  variety  of  conditions,  such  as  different  laboratories,  different  analysts,  different
instruments etc. Normally expressed as the lack of influence on test results of operational and
environmental variables of the analytical method. Ruggedness is a measure of reproducibility
of  test  results  under  the  variation  in  condition  normally  expected  from  laboratory  to
laboratory and from analyst to analyst.
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Determination of ruggedness:
By analysis of aliquots from homogenous lots in different laboratories, by different
analysis, using operational and environmental conditions that may differ but are still within
the  specified  parameters  of  the  assay.  Degree  of  reproducibility  of  test  results  is  then
determined as a function of the assay variables.
SYSTEM SUITABILITY:-
According to USP system suitability are an integral part of chromatographic methods.
These tests verify that the resolution and reproducibility of the system are adequate for the
analysis to be performed. One consequence of the evaluation of robustness and ruggedness
should be  that  a  series  of  system suitability  parameters  is  established  to  ensure  that  the
validity of the analytical method is maintained whenever used. 
System  suitability  tests  are  based  on  the  concept  that  the  equipment,  electronics,
analytical operations and samples constitute an integral  system that can be evaluated as a
whole.
ROBUSTNESS:
Robustness of an analytical method is measure of its capacity to remain unaffectedly
small  but  deliberate  variations  in  method  parameters  and  provides  an  indication  of  its
reliability during normal usage.
The  parameters,  which  are  recommended  by  International  Committee  of
Harmonization to be validated for different types of assays, are shown in following table
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INTERNATIONAL COMMITTEE ON HARMONIZATION (ICH)
RECOMMENDATION
ASSAY TYPE VALIDATIONS
Identification tests area intended to ensure
the identity of an analyte in a sample. This is
normally achieved by comparison of a
property of the sample to that of a reference
standard.
Specificity
Impurities Quantitation are intended to
accuately reflect the purity characteristic of
the sample. Different validation
characteristics are required for a quantitative
test than for a limit test.
Accuracy, Precision, Specificity, Detection
limit, Quantitation limit, Linearity, Range.
Impurites limit are intended to reflect the
purity characteristics of the sample
Specificity, Detection limit
Content/ Potency; Dissolution are intended to
measure the analyte present in a given
sample. A quantitative measurement of the
major components in the drug substance.
Accuracy, Precision, Specificity, Linearity,
Range.
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In the ICH-2QA: Text on Validation Analytical procedures, validation characteristics
versus type of analytical procedures are shown in following table
VALIDATION CHARACTERISTICS VERSUS TYPE OF ANALYTICAL PROCEDURES
TEST FOR IMPURITIES
Type  of
procedure
Identification Quantitation Limit
Dissolution
Measurement
(content/Potency)
Accuracy No Yes No Yes
Precision
/repeatability
No Yes No Yes
Intermediate
Precision
No Yesa No Yesa
Specificity Yes Yes Yes Yes
Detection limit No Nob Yes No
Quantitation
limit
No Yes No No
Linearity No Yes No Yes
Range No Yes No Yes
a. When reproducibility is performed. Intermediate precision is not needed.
b. May be needed in some cases.
The  ICHQ2B:  Validation  of  Analytical  procedures,  describes  the  main  objective  of
validation as  the ability  of  an analytical  procedure  to  demonstrates  that  the procedure  is
suitable for its  intended purpose.  The document  stresses  that  well-characterized reference
materials, with documented purity, should be used throughout the validation study.
The comparison of different official guidelines in case of parameters required to be
validated for different assays is shown in following  table
COMPARATIVE TABLE REPRESENTING FDA, USP AND ICH REQUIREMENTS
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CRITERIA GMP FDA USP ICH
Accuracy X X X X
Precision X X X
Specificity X X X X
Detection limit X X
Quantitation
limit
X X
Linearity X X X
Range X X
Reproducibility X X
Sensitivity X
Recovery X
Ruggedness X X
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LITERATURE REVIEW
Yanamandra R et  al20.,  developed a new rapid,  simple,  sensitive,  selective and accurate
reversed-phase stability-indicating Ultra  Performance Liquid Chromatography (RP-UPLC)
technique for the assay of Tolterodine Tartrate in pharmaceutical dosage form, human plasma
and urine samples. The developed UPLC method is superior in technology to conventional
HPLC  with  respect  to  speed,  solvent  consumption,  resolution  and  cost  of  analysis.
Chromatographic run time was 6 min in reversed-phase mode and ultraviolet detection was
carried  out  at  220  nm  for  quantification.  Efficient  separation  was  achieved  for  all  the
degradants  of  Tolterodine  Tartrate  on  BEH C18 sub-2-µm Acquity  UPLC column using
Trifluoroacetic  acid and acetonitrile  as  organic  solvent  in  a  linear  gradient  program. The
active pharmaceutical ingredient was extracted from tablet dosage form using a mixture of
acetonitrile and water as diluent. The calibration graphs were linear and the method showed
excellent recoveries for bulk and tablet dosage form. The test solution was found to be stable
for 40 days when stored in the refrigerator between 2 and 8 °C. The developed UPLC method
was  validated  and meets  the requirements  delineated  by the International  Conference  on
Harmonization (ICH) guidelines with respect to linearity, accuracy, precision, specificity and
robustness. The intra-day and inter-day variation was found be less than 1%. The method was
reproducible and selective for the estimation of Tolterodine Tartrate.  Because the method
could effectively separate the drug from its degradation products, it can be employed as a
stability-indicating one.
Dwibhashyam VS  et al21., developed a selective, sensitive, and rugged reverse phase-high
performance liquid chromatographic method for the determination of Tolterodine tartrate in
routine quality control samples. The mobile phase consisted of acetonitrile:phosphate buffer
(pH 7.0) in 55:45 v/v ratio. The mobile phase was also used for the extraction of tolterodine
tartrate from its formulations. The chromatography was carried out on a Luna 100A, C-18 (5-
micro,  250 x 4.60 mm) column.  The software  used in the chromatographic  analysis  was
Empower  Photodiode   Array  (PDA)  software  (Waters,  Milford,  CT).  The  UV
spectrophotometric determination was done at 210 nm. Retention time was found to be about
7.0 +/- 0.5 min. The standard curve was linear (r2 = 0.9997) over the concentration range of
0.1-0.3 mg/mL. The method was found to be accurate,  precise,  specific,  and rugged. The
limit of detection was 0.16 microg/mL and the limit of quantification was 0.489 microg/mL.
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With a short chromatographic run time, the proposed method can be used for the estimation
of large number of quality control samples in a short period.
Xia  ZL  et  al22.,developed  a  high-performance  liquid  chromatographic  method  for  the
separation of the enantiomers of tolterodine tartarate. The proposed method was applied to
the  determination  of  (S)-isomer  in  (R)-tolterodine  tartarate,  and  satisfactory  results  were
obtained. The enantiomers of tolterodine tartarate were separated on a Chiralpak AD-H (250
mm x  4.6  mm)  column containing  amylase  tris-(3,5-dimethylphenyl-carbamate)  at  room
temperature. The mobile phase consisted of n-hexane and isopropyl alcohol in the ratio of
85:15 (v/v) with 0.075% triethylamine (TEA) and 0.05% trifluoroacetic acid (TFA) as the
additive.  The flow rate was kept at 0.5 ml/min, and UV detection wavelength was set at 283 
nm. The calibration curves of (S)-enantiomer in the concentration range from 0.05 microg/ml
to  1  microg/ml  range  were  linear.  The  relative  standard  deviations  of  within-day  and
between-day were less than 2% (n = 3). The limit of detection (LOD) was 0.75 ng (S/N = 3)
and  the  limit  of  quantification  (LOQ)  was  0.05  microg/ml  (RSD  <  4.1%,  n  =  3).  The
determination recoveries of the (S)-enantiomer were in the range of 98.2-104.8%. The results
demonstrated that the developed HPLC method was a reliable,  simple technique and was
applicable to the purity determination of (R)- tolterodine tartarate.
Guan  Y  et  al23.,developed  and  validated  a  sensitive,  selective  and  efficient  liquid
chromatographic/tandem mass spectrometric (LC/MS/MS) method  for the determination of
glucosamine  in  healthy  human  urine.  Urine  samples  were  extracted  by  acetonitrile  and
derivatized with o-phthalaldehyde/3-mercaptopropionic acid. Analysis was then carried out
using  ESI source  and  methanol/0.2% ammonium acetate-0.1% formic  acid  mobile  phase
gradient elution, with tolterodine tartrate as the internal standard. The linear calibration curve
ranged from 0.41µg/ml to  82.7µg/ml. The intra-day and inter-day precisions were less than
3.93% and 10.0%, respectively. The extraction recoveries determined at three concentration
levels  were higher than 88.6%. The method was successfully applied for determining the
urine concentration of glucosamine up to 24h after oral  administration of 1g glucosamine
sulfate dispersible table (containing 785.08mg glucosamine) from a clinical pharmacokinetic
study in healthy volunteers.
Macek J  et al24.,developed a rapid and reliable method to quantitate tolterodine and its 5-
hydroxymethyl  metabolite  in  human  plasma  using  liquid  chromatography-electrospray
tandem  mass  spectrometry.  The  assay  was  based  on  liquid-liquid  extraction  of  the
compounds  from  plasma  with  tert-butylmethylether  and  hydrophilic  interaction
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chromatography  performed  on  a  silica  column  (30mmx4.6mm,  3microm  particles),  the
mobile phase consisted of acetonitrile-20mM ammonium acetate (70:30, v/v). Quantification
was through positive-ion m` ode  and  selected  reaction  monitoring  at  m/z  326-->147  for
tolterodine,  342-->223 for the 5-hydroxymethyl  metabolite and 260-->183 for the internal
standard propranolol, respectively. The lower limit of quantitation was 49 and 46pg/ml using
0.5ml  of  plasma  for  the  parent  drug  and  its  metabolite,  respectively  and  linearity  was
observed  up  to  30ng/ml.  Within-day  and  between-day  precision  expressed  by  relative
standard deviation was less than 11% and inaccuracy did not exceed 7% at all levels. The
assay was applied to the analysis of samples from a pharmacokinetic study.
Xia  ZL  et  al25.,developed  a  high-performance  liquid  chromatographic  method  for  the
separation of the enantiomers of tolterodine tartarate. The proposed method was applied to
the  determination  of  (S)-isomer  in  (R)-tolterodine  tartarate,  and  satisfactory  results  were
obtained. The enantiomers of tolterodine tartarate were separated on a Chiralpak AD-H (250
mm x  4.6  mm)  column containing  amylase  tris-(3,5-dimethylphenyl-carbamate)  at  room
temperature. The mobile phase consisted of n-hexane and isopropyl alcohol in the ratio of
85:15 (v/v) with 0.075% triethylamine (TEA) and 0.05% trifluoroacetic acid (TFA) as the
additive.  The flow rate was kept at 0.5 ml/min, and UV detection wavelength was set at 283 
nm. The calibration curves of (S)-enantiomer in the concentration range from 0.05 microg/ml
to  1  microg/ml  range  were  linear.  The  relative  standard  deviations  of  within-day  and
between-day were less than 2% (n = 3). The limit of detection (LOD) was 0.75 ng (S/N = 3)
and  the  limit  of  quantification  (LOQ)  was  0.05  microg/ml  (RSD  <  4.1%,  n  =  3).  The
determination recoveries of the (S)-enantiomer were in the range of 98.2-104.8%. The results
demonstrated that the developed HPLC method was a reliable,  simple technique and was
applicable to the purity determination of (R)- tolterodine tartarate.
Böttiger Y et al26.,studied about the  hydroxylation of omeprazole and  measured as the ratio
of omeprazole/5-hydroxyomeprazole in a plasma sample taken 3 h after an oral  dose,and
claimed that it  is an established method to determine CYP2C19 activity,  and the ratio of
omeprazole AUC/omeprazole sulfone AUC has been used for assessing CYP3A4 activity.
The aim of this study was to determine whether the latter ratio from a  single 3-h sample can
also be used for CYP3A4 phenotyping.  Plasma levels of omeprazole and omeprazole sulfone
were analyzed by reversed-phase high-performance liquid chromatography in a blood sample
drawn 3 h after intake of a single oral 20-mg dose of omeprazole by 22 healthy subjects and
five patients with newly diagnosed epilepsy. The procedure was repeated on the 4th day of
200  mg  of  ketoconazole  intake  (10  subjects),  after  3  weeks  of  150-200 mg twice-daily
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carbamazepine  (five  patients),  and  on  the  6th  day  of  4  mg  twice-daily  tolterodine  (12
subjects).  Five  subjects  also took 100 mg and 50 mg of  ketoconazole for  3  days  before
concomitant intake with omeprazole. The mean log10(omeprazole/omeprazole sulfone) ratio
was 0.18 3 h after intake of omeprazole alone. After concomitant intake of ketoconazole, the
corresponding value was 1.38 (p<0.001); after intake of carbamazepine it was -0.42 (p<0.05);
and after tolterodine it was 0.29 (not significant). In the five  subjects taking increasing doses
of  ketoconazole,  the ratio  was 0.11, 0.79, 1.2,   and 1.5 after  0,  50,  100, and 200 mg of
ketoconazole, respectively. The correlation between the metabolic ratios from the AUC((0-
6h)) and from the single 3-h samples was very good, with a correlation coefficient of 0.92
(p<0.001). A single blood sample taken 3 h after intake of 20 mg of omeprazole  can be
reliably used to phenotype for both CYP2C19 and CYP3A4 activity.
Zhang  B  et  al27.,developed  a  selective  and  sensitive  high  performance  liquid
chromatography-electrospray ionization mass spectrometry method for the determination of
tolterodine  tartrate  in  human  plasma.  With  oxybutynin  as  internal  standard,  tolterodine
tartrate was extracted from plasma with n-hexane: isopropanol (95:5,  v/v). The organic layer
was evaporated and the residue was redissolved in mobile  phase comprised of acetonitrile-
water  (10  mM  CH3COONH4,  pH  3.0)=50:50  (v/v).  An  aliquot  of  10  microl  was
chromatographically analyzed on a prepacked Shimadzu Shim-pack VP-ODS C18 column
(150 mmx2.0 mm I.D.) by means of selected-ion monitoring (SIM) mode mass spectrometry.
Standard curves were linear (r=0.9993) over the concentration range of 0.1-30.0 ng/ml and
had good accuracy and precision. The within- and between-batch precisions were within 10%
relative  standard deviation. The limit of detection (LOD) was 0.05 ng/ml. The validated LC-
ESI-MS method has been used successfully to study tolterodine tartrate  pharmacokinetic,
bioavailability and bioequivalence in 20 healthy male volunteers.
Hosseinpour F  et  al28.,carried  a  work  on the  following  ,Porcine  CYP2D25,  microsomal
vitamin D(3) 25-hydroxylase,  catalyzes the essential   first step in the bioactivation of the
prohormone vitamin D(3).  Although CYP2D25 shows a high degree of sequence identity
with other members of the CYP2D subfamily, such as human CYP2D6, the vitamin D(3) 25-
hydroxylase  activity  is  a  unique  property  among  CYP2D  enzymes.  In  addition  to  25-
hydroxylation, CYP2D25 also metabolizes the drug tolterodine. In this study, CYP2D25 was
functionally  expressed  in  the  Saccharomyces  cerevisiae  W(R)  strain  and  site-directed
mutagenesis  was  used  to  study  the  role  of  substrate  recognition  site  3  (SRS-3)  for  the
catalytic specificity of CYP2D25. Five residues in SRS-3 of CYP2D25 were  simultaneously
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mutated to the equivalent residues in CYP2D6, an enzyme not active in 25-hydroxylation.
Western blot analysis of microsomes from transformed yeast cells showed that both the wild-
type and mutant CYP2D25 were expressed at comparable levels. The 25-hydroxylase activity
of recombinant mutant CYP2D25 was completely lost whereas the activity toward tolterodine
remained virtually unaffected. The results implicate that residues in SRS-3 of CYP2D25 are
important determinants for its function in vitamin D(3) metabolism.
Swart R et al29.,developed a method where a capillary solid-phase extraction (SPE) system
has been coupled directly to electrospray tandem mass spectrometry for quantification of free
tolterodine  and  metabolite  concentrations  in  plasma.  The  unbound  fraction  of  these
compounds was obtained by ultrafiltration of plasma. The ultrafiltrate was directly injected
onto the SPE capillary (4 mm x 200 microm, 5 microm C18). After desalting and clean-up of
the sample, the analytes were eluted in backflush mode with methanol-1 mM triethylamine
(70:30,  v/v),  providing considerable  solute  focusing.  Elution from the  SPE capillary was
improved  by inserting  a  short  trapping  capillary between  the  SPE capillary  and  the  MS
interface,  by  which  analyte  focusing  was  increased.  The  unresolved  compounds  eluted
simultaneously  with  the  remaining  matrix  compounds  and  were  detected  in  a  multiple-
reaction monitoring (MRM) mode. No interference of the sample matrix on detection was
observed,allowing aqueous standards  to  be used for  calibration.  Linear  calibration  curves
were obtained between 0.05 and 1000 ng/ml (corresponding to 150 pM-3 microM) and  the
limit  of  detection  was  50  pg/ml  injecting  10  microl.  Equilibration  of  the  SPE capillary,
sample loading, elution and detection took less then 6 min per sample.
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AIM AND OBJECTIVE OF WORK
             Literature review reveals that few methods have been published for analysis of
Tolterodine  tartrate  tablets  in  the  biological  fluids  and samples.  But  the methods are
somewhat costlier as they are using costlier solvents and the detectors used by them are
mostly PDA detectors.  So, the objective of this work was to develop and validate an
isocratic  RP-HPLC  method  for  quantitative  analysis  of  Tolterodine  tartrate  in  tablet
dosage form which is very easy for the analyst to analyse and by using the economic
solvents with UV detector as this detector is commonly available detector.
                                              
PLAN OF WORK
Method Development Parameters Done By RP-HPLC
 Selection of detector wavelength
 Selection of column
 Selection of mobile phase composition and pH
 Selection of flow rate
Validation of  the  Developed Method
a) Linearity
b) System precision
c) Method precision
d) Specificity
e) Accuracy
f) Ruggedness
g) Robustness
h) Limit of detection and quantification
i) Solution stability
j) System suitability
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DRUG PROFILE
Tolterodine tartrate
Description                : White-to-Off-White Crystalline Powder
IUPAC Name :  (R)-2-(3-(Bis(1-methylethyl)amino)-1-phenylpropyl)-4-
methylphenol (R-(R',R'))-2,3-dihydroxy butanedioate
Synonym                   : (+)-R)-2-{a-[2-(Diisopropylamino)ethyl]benzyl}-p-cresol tartrate
Chemical Formula : C26H37NO7 
Chemical Structure :                               
                            
Molecular Weight :  475.6
Melting Point : 205-210°C 
Solubility : The solubility in water is 12 mg/mL. It is soluble in methanol,    
                                       slightly soluble in ethanol, and practically insoluble in toluene.
Category                   : A muscarinic receptor antagonist. Used in the treatment of urinary
                                      incontinence.
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INSTRUMENTS AND REAGENTS
Instruments
Sl.No Name of the instrument Make Model
1 UV-VIS Double beamSpectrophotometer Shimadzu AL-2401
2 HPLC-UV Agilent LC-2011
3 Millipore Millipore Simplicity
4 Electronic balance Shimadzu AD220D
Reagents and Chemicals
S.NO Name Grade Manufacturer/Supplier
1 ACN                 HPLC MERCK
2
 Di sodium hydrogen
Phosphate
HPLC MERCK
3 Millipore water - -
4 Phosphoric acid HPLC MERCK
Standard
          The reference standard Tolterodine tartrate was obtained as gift sample and authenticity
and purity of the sample was certified by Ranbaxy.
Formulation
Label Claim            : 1mg
Brand Name           : Roliten
Company Name     : Ranbaxy
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METHOD DEVELOPMENT AND OPTIMIZATION
1. Selection of wavelength
             The known concentration of Tolterodine tartrate was taken and dissolved
in water. The resulting solution was then scanned between 200 to 400 nm and is
shown in fig 1.Maximum absorbance was found at 302nm and it was selected for
the analysis of  Tolterodine tartrate.
2. Optimization of Chromatographic Parameters
a. Selection of mode of operation
             As the drug was polar in nature, RP-HPLC was preferred.
b. Selection of mobile phase 
              The method development of Tolterodine tartrate required adequate
resolution of  the drug peak in the chromatogram. Different  solvent systems
were tried to get the proper resolution
3. Preparation of mobile phase
               Acetonitrile and Di sodium hydrogen phosphate in the ratio 27:73 was
taken and the pH of the mobile phase was maintained at 7.6 with phosphoric
acid and it was filtered. Then it was degassed.        
4. Selection of flow rate
               The flow rate for Tolterodine tartrate was tried at different rates. Finally
1ml/min was selected at which the peak was free from any fronting or tailing
effects. 
    Preparation of Phosphate Buffer (pH 7.6):
               Place 50 ml of 0.2M potassium dihydrogen phosphate in a 200ml
volumetric flask, add 42.4ml of 0.2M sodium hydroxide and then add water to
volume.
5. Determination of retention time
    Standard solution of Tolterodine tartrate:
                100mg of Tolterodine tartrate standard was accurately weighed and
transferred  into a  100ml  volumetric  flask.  Then  diluent  was  added  and  the
volume was made upto the mark. From the stock solution 10ml was pipetted
out into a 100ml volumetric flask and the volume was made up to the mark
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with diluent. Then from the resulting solution 1ml was taken and made upto
10ml with diluents.  The solution was then filtered through 0.45µ  membrane
filter.
                 20µl of the solution was injected and the chromatogram was recorded   
      and it is shown in fig 3.
FIXED CHROMATOGRAPHIC CONDITIONS
Instrument                      : AGILENT LC-2011with UV-VIS Detector
Column                           : C18
Wavelength                     : 302nm
Flow rate                         : 1ml/min
Injection                          : 20µl
Mobile Phase                  : Buffer: ACN (73:27) pH maintained at 7.6 with   
                                           phosphoric acid                                          
Retention time                 : 12.994 mins
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QUANTITATIVE ESTIMATION OF THE DRUG
Sample             :       Tolterodine tartrate
Label claim      :       1mg
Standard solution of Tolterodine tartrate
              100mg of Tolterodine tartrate standard was accurately weighed and
transferred into a 100ml volumetric flask. Then diluent was added and the volume
was made upto the mark. From the stock solution 10ml was pipetted out into a
100ml volumetric flask and the volume was made up to the mark with diluent.
Then from the resulting solution 1ml was taken and made upto 10ml with diluents.
The solution was then filtered through 0.45µ membrane filter.
Sample preparation
              20 Tolterodine tartrate tablets were randomly selected, weighed and their
average  weight  was  calculated.  Then  the  sample  equivalent  to  100mg  was
weighed and transferred into a 100ml volumetric flask. Diluent was added and
then the volume was made up to the mark. The solution was then shaken well to
dissolve the contents and then filtered.10ml of the filtrate was diluted to 100ml
with diluent. Then from the resulting solution 1ml was taken and made upto 10ml
with diluents. The solution was then filtered through 0.45µ membrane filter.
The amount of Tolterodine tartrate present in the tablet formulation was
calculated by comparing the peak area of the standard and sample which is given
in fig 5 & 6. The reports are given in table 1.
Amount of drug present in the tablet =
Sample area      Standard dilution      Potency
------------------ x --------------------- x -------------- x Average weight of tablet
Standard area       Sample dilution       100
             Amount present
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Percentage content = ----------------------- x 100
Label claim
VALIDATION
              Validation of an analytical method is a process to establish by laboratory
studies that the performance characteristics of the method meet the requirements
for the intended analytical application. Performance characteristics are expressed
in terms of analytical parameters.
Design of experiment:
Typical analytical parameters used in assay validation are,
• Specificity
• Linearity and range
• Limit of quantification
• Limit of detection
• Accuracy
• Precision
- System precision
- Method precision
• Robustness
• Ruggedness
• System suitability studies
- Resolution 
- Number of theoretical plates
- The tailing factor 
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LINEARITY AND RANGE
              Linearity of an analytical method is its ability to elicit test results that are
directly proportional  to the concentration of analyte  in samples  within a  given
range.
Determination:
              The linearity of the analytical method for the assay was demonstrated by
injecting the different concentrations of the standard preparation in the range of
10-100% into the chromatograph, covering 10 different concentrations. A plot was
drawn between the concentration vs peak response of Tolterodine tartrate.  The
slope, intercept and regression coefficient from the plot obtained for concentration
vs peak response of Tolterodine tartrate was reported.
Method:
Preparation of standard solution
              100mg of Tolterodine tartrate standard was transferred into 100ml
volumetric  flask  and  diluent  was  added.  The  volume was  then  made  up  with
diluent. From the stock solution 10ml was pipetted out into a 100ml volumetric
flask and the volume was made up to the mark with diluent.  From the resulting
solution 0.2,0.4,0.6,0.8,  1,1.2,1.4,1.6,1.8  and 2 were  transferred  to 10 different
10ml volumetric flasks and the volumes were made up with diluent. The solutions
were then filtered through 0.45µ membrane filters. 
 20 lµ  of the resulting solutions were injected and chromatograms were
recorded. The chromatograms of Tolterodine tartrate are shown in figure 7-16.
The correlation coefficient  and percentage  curve fitting were calculated
from the following formula,
∑
−
−−
=
yx SS1n
)yy)(XX(
R
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Where, x = concentration, y = instrumental response, Sx = Std. Deviation of x Sy =
Std. Deviation of y
Percentage curve fitting = 100x correlation coefficient 
Acceptance Criteria
 Correlation coefficient should not be less than 0.97%
 Curve fitting should not be less than 99.7%
            The linearity Data and analytical performance parameters of Tolterodine
tartrate  is  shown in  Table  2-3  and  calibration  curve  of  Tolterodine  tartrate  is
shown fig 17.
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PRECISION
              Precision of an analytical method is the degree of agreement among
individual  test  results  when  the  procedure  is  applied  repeatedly  to  multiple
sampling  of  a  homogenous  sample.  Precision  of  analytical  method  is  usually
expressed as the standard deviation and relative standard deviation.
SYSTEM PRECISION
              The system precision was evaluated by measuring the peak response of
drug  for  six  replicate  injections  of  the  standard  solution  as  per  the  proposed
method.
Acceptance  criteria:  The  relative  standard  deviation  for  the  six  standard
preparations of the same batch should not be more than 2.0%
Blank solution
      Mixture of Buffer and ACN in the ratio 73:27 was taken and degassed.          
Standard solution of Tolterodine tartrate
                       100mg of Tolterodine tartrate standard was accurately weighed and
transferred  into a  100ml  volumetric  flask.  Then  diluent  was  added  and  the
volume was made upto the mark. From the stock solution 10ml was pipetted
out into a 100ml volumetric flask and the volume was made up to the mark
with diluent. Then from the resulting solution 1ml was taken and made upto
10ml with diluents.  The solution was then filtered through 0.45µ  membrane
filter.
                  In the same manner five other standard solutions were also prepared.
20µl of the working standards were injected. The peak responses were measured
from the chromatograms shown in fig 18-23and system precision data are shown
in table 4.
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The standard deviation and relative standard deviation were calculated 
from the statistical formula
Standard deviation = 
1n
)xx( 2
−
−
σ
∑
x = sample, x  = mean value of sample, n = number of sample
                        Relative standard deviation = 100x
x
σ
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METHOD PRECISION
             The method precision was determined by preparing the sample of single
batch of Tolterodine tartrate tablets for six times and analysed as per the proposed
method.
Acceptance criteria: The relative standard deviation for the assay values of six
sample preparations of the same batch should be not more than 2.0%
Blank solution
            Mixture of Buffer and ACN in the ratio 73:27 was taken and degassed.
Sample preparation   
            20 Tolterodine tartrate tablets were randomly selected, weighed and their
average  weight  was  calculated.  Then  the  sample  equivalent  to  100mg  was
weighed and transferred into a 100ml volumetric flask. Diluent was added and
then the volume was made up to the mark. The solution was then shaken well to
dissolve the contents and then filtered.10ml of the filtrate was diluted to 100ml
with diluent. Then from the resulting solution 1ml was taken and made upto 10ml
with diluents. The solution was then filtered through 0.45µ  membrane filter. The
procedure was repeated another five times to give a set of 6 replicate solutions.
 20 lµ of working sample solution were injected and the chromatograms
were recorded and shown in fig 24-29 and method precision data are shown in
table 5.
The  standard  deviation  and  relative  standard  deviation  were  calculated
from the statistical formula
Standard deviation = 
1n
)xx( 2
−
−
σ
∑
x = sample, x  = mean value of sample, n = number of sample
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                        Relative standard deviation = 100x
x
σ
SPECIFICITY
             The specificity of an analytical method is its ability to measure accurately
and specifically the analytes in the presence of compounds that may be expected
to be present in the sample matrix
Determination
             The specificity of the analytical method was determined by injecting the
placebo solution under the same experimental conditions as the assay.
Preparation of placebo
              Placebo was prepared by mixing all the excipients other than the active
ingredients.
Procedure
               About 8.5gm of placebo was accurately weighed and transferred to a
100ml volumetric flask. Then diluent was added and the volume was made up to
the mark. The solution was then filtered through Whatmann filter paper. 10ml of
the above solution was pipetted into a 100ml volumetric flask and the volume was
made up with millipore water.  From the resulting solution 1ml was taken and
made upto 10ml. The solution was then filtered through 0.45µ membrane filter.
             20µl of the solution was injected and the chromatogram was recorded
which is shown in fig 31.
Preparation of Tolterodine tartrate standard
             100mg of Tolterodine tartrate standard was accurately weighed and transferred
into a 100ml volumetric flask. Then diluent was added and the volume was made
upto  the  mark.  From the  stock  solution  10ml  was  pipetted  out  into  a  100ml
volumetric flask and the volume was made up to the mark with diluent. Then from
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the resulting solution 1ml was taken and made upto 10ml with diluents.   The
solution was then filtered through 0.45µ membrane filter.
 20µl of the solution was injected and the chromatogram was recorded which is
shown in fig 32.
Preparation of standard + placebo    
             100mg of accurately weighed standard and 8.5gm of placebo was
transferred into a 100ml volumetric flask. Then diluent was added and the volume
was made upto the mark. From the stock solution 10ml was pipetted out into a
100ml volumetric flask and the volume was made up to the mark with diluent.
From  the  resulting  solution  1ml  was  pipetted  out  and  made  upto  10ml  with
diluent. The solution was then filtered through 0.45µ membrane filter.
           20µl of the solution was injected and the chromatogram was recorded
which is shown in fig 33 and the data values are given in table 6
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ACCURACY
The  accuracy  of  an  analytical  method  is  the  closeness  of  test  results
obtained by that method to the true value. Accuracy may often the expressed as
percent recovery by the assay of known added amounts of analyte.
Determination:
The  accuracy  of  the  analytical  method  is  determined  by  applying  the
method  to  analyzed  samples,  to  which  known  amounts  of  analyte  have  been
added. The accuracy is calculated from the test results as the percentage of analyte
recovered by the assay.
Acceptance Criteria: Percentage recovery should be within 98-102%
Procedure:
             Different concentrations of Tolterodine tartrate were prepared by taking
different weights and dissolved in diluent. From the resulting solutions, suitable
dilutions are made to give concentrations  of 80%, 100% and 120%. The peak
areas of the different concentration of solutions are then determined in triplicates,
as shown in fig 34-42 and values are given in table 7.The amount is calculated
using the equation
                              Sample area   Standard dilution        
   Accuracy=        ------------------ x       --------------------- x    Potency          
                 Standard area             Sample dilution
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RUGGEDNESS
             The ruggedness of an analytical method is degree of reproducibility of test
results obtained by the analysis of the same samples under a variety of normal test
conditions, such as different laboratories, different analysts, different instruments,
different  lots  of  reagents,  different  elapsed  assay  times,  different  assay
temperatures, different days, etc.
              Ruggedness is normally expressed as a lack of influence on test results of
operational and environmental variables of the analytical method.
Procedure
Standard solution of Tolterodine tartrate
           100mg of  Tolterodine  tartrate  standard  was  accurately  weighed  and
transferred into a 100ml volumetric flask. Then diluent was added and the volume
was made upto the mark. From the stock solution 10ml was pipetted out into a
100ml volumetric flask and the volume was made up to the mark with diluent.
Then from the resulting solution 1ml was taken and made upto 10ml with diluents.
The solution was then filtered through 0.45µ membrane filter.
Sample preparation
         20 Tolterodine tartrate tablets were randomly selected, weighed and their
average  weight  was  calculated.  Then  the  sample  equivalent  to  100mg  was
weighed and transferred into a 100ml volumetric flask. Diluent was added and
then the volume was made up to the mark. The solution was then shaken well to
dissolve the contents and then filtered.10ml of the filtrate was diluted to 100ml
with diluent. Then from the resulting solution 1ml was taken and made upto 10ml
with diluents. The solution was then filtered through 0.45µ membrane filter.
Method:
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The standard stock solution and sample stock solution were prepared by different
analysts on different days & different instruments and the resulting solutions were
injected and the chromatograms were recorded which is shown in fig 43-62. The
ruggedness of the method and report of the method is shown in table 8-10.
ROBUSTNESS
            Robustness of an analytical method is the measure of its capacity to remain
unaffected by small but deliberate variations in method parameters and provides
an indication of its reliability during normal usage.
Determination:
The robustness  of  an analytical  method was  determined  by analysis  of
aliquots from homogenous lots by differing physical parameters that may differ
but were still within the specified parameter of the assay for example change in
physical parameters like flow rate and mobile phase ratio.
Acceptance Criteria:
            The %RSD for the assay values of Tolterodine tartrate in Roliten tablets
1mg obtained under deliberately modified chromatographic conditions should not
be  more  than  2.0%.  The  difference  between  the  assay  under  the  modified
conditions and the assay obtained under precision should not be more than 2.0%
Method:
Preparation of blank
Mixture  of  Buffer  and  ACN  in  the  ratio  73:27  was  taken  and  degassed.
Preparation of standard solution
           100mg of Tolterodine tartrate  standard was accurately weighed and
transferred into a 100ml volumetric flask. Then diluent was added and the volume
was made upto the mark. From the stock solution 10ml was pipetted out into a
100ml volumetric flask and the volume was made up to the mark with diluent.
Then from the resulting solution 1ml was taken and made upto 10ml with diluents.
The solution was then filtered through 0.45µ membrane filter.
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Preparation of sample solution
             20 Tolterodine tartrate tablets were randomly selected, weighed and their
average  weight  was  calculated.  Then  the  sample  equivalent  to  100mg  was
weighed and transferred into a 100ml volumetric flask. Diluent was added and
then the volume was made up to the mark. The solution was then shaken well to
dissolve the contents and then filtered.10ml of the filtrate was diluted to 100ml
with diluent. Then from the resulting solution 1ml was taken and made upto 10ml
with diluents. The solution was then filtered through 0.45µ membrane filter.
Procedure
              20µl of blank, standard and sample preparations were injected into the
chromatograph  which  was  set  under  deliberately  modified  chromatographic
conditions and the chromatograms were recorded. The graphs are shown in fig 63-
86 and the results are shown in table 11-18.
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SOLUTION STABILITY
           To establish the stability of analytical solutions the standard and sample
solutions were injected at periodic intervals upto 24hrs.
Acceptance criteria:  The %RSD of peak response for the major peak of both
standard and sample solutions at periodic intervals should not be more than 2.0%
Blank Solution
Mixture  of  Buffer  and  ACN  in  the  ratio  73:27  was  taken  and  degassed.
Preparation of standard solution
          100mg of  Tolterodine  tartrate  standard  was accurately  weighed  and
transferred into a 100ml volumetric flask. Then diluent was added and the volume
was made upto the mark. From the stock solution 10ml was pipetted out into a
100ml volumetric flask and the volume was made up to the mark with diluent.
Then from the resulting solution 1ml was taken and made upto 10ml with diluents.
The solution was then filtered through 0.45µ membrane filter.
Preparation of sample solution
          20 Tolterodine tartrate tablets were randomly selected, weighed and their
average  weight  was  calculated.  Then  the  sample  equivalent  to  100mg  was
weighed and transferred into a 100ml volumetric flask. Diluent was added and
then the volume was made up to the mark. The solution was then shaken well to
dissolve the contents and then filtered.10ml of the filtrate was diluted to 100ml
with diluent. Then from the resulting solution 1ml was taken and made upto 10ml
with diluents. The solution was then filtered through 0.45µ membrane filter.
Procedure
51
          20µl of blank, standard and sample preparations were injected separately
into the chromatograph and the peak responses were measured for the major peak
and they are shown in Fig87-122  and the data values are given in table 19
LIMIT OF DETECTION
It is the lowest amount of analyte in a sample that can be detected but not
necessarily quantified as an exact value under the stated, experimental conditions.
Several approaches for determining the detection limit are possible, depending on
whether the procedure is non-instrumental or instrumental. Approaches other than
those listed below may be acceptable.
1. Based on visual evaluation
2. Based on signal-to-noise.
3. Based on the standard deviation of the Response and slope.
Here the calculations were made on the basis of standard deviation of the response
and slope.
Based on the standard deviation of the Response and slope:
                A specific calibration curve was studied using samples containing an
analyte  in  the  range  of  detection  limit.  The  residual  standard  deviation  of  a
regression line or the standard deviation of y-intercepts of regression lines may be
used as the standard deviation.
The detection limit may be expressed as:
S
3.3LOD σ=
Where, σ = standard deviation of the response
S=slope of the calibration curve
The slope S was estimated from the calibration curve of the analyte. 
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The data are given in table 20.
LIMIT OF QUANTITATION
It is the lowest amount of analyte in a sample which can be quantitatively
determined  with  suitable  precision  and  accuracy. Several  approaches  for
determining  the  quantitation  limit  are  possible,  depending  on  whether  the
procedure  is  a  non-instrumental  or  instrumental.  Approaches  other  than  those
listed below may be acceptable.
1. Based on visual evaluation
2. Based on signal-to-noise.
3. Based on the standard deviation of the Response and slope.
Here the calculations  were  made on the basis of the standard deviation of the
response and slope.
Based on the standard deviation of the Response and slope:
            A specific calibration curve was studied using samples containing the
analyte  in the range of quantitation limit. The residual standard deviation of a
regression line or the standard deviation of y-intercepts of regression lines may be
used as the standard deviation.
The quantitation limit may be expressed as:
S
10LOQ σ=
Where, σ = standard deviation of the response
S=slope of the calibration curve
The slope S may be estimated from the calibration curve of the analyte. 
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The data are given in table 21.
SYSTEM SUITABILITY 
            System suitability testing is an integral part of many analytical procedures.
The tests  are  based  on  the  concept  that  the  equipment,  electronics,  analytical
operation and  sample to  be  analysed  constitute  an integral  system that  can be
evaluated  as  such.   System  suitability  test  parameters  to  be  established  for  a
particular procedure depend on the type of procedure being validated.
Acceptance Criteria:
• The column efficiency is not less than 2000 theoretical plates
• The tailing factor for the analyte peak is not more than 2.0
• The relative standard deviation for the replicate injection is not more than
2.0%
Determination
            To determine the suitability of chromatographic system described for the
method of analysis by establishing system suitability parameters like peak tailing
factor,  number  of  theoretical  plates  and  the  %RSD  of  Tolterodine  standard
preparation on daily basis
Preparation of standard solution
            100mg of Tolterodine tartrate standard was accurately weighed and
transferred into a 100ml volumetric flask. Then diluent was added and the volume
was made upto the mark. From the stock solution 10ml was pipetted out into a
100ml volumetric flask and the volume was made up to the mark with diluent.
Then from the resulting solution 1ml was taken and made upto 10ml with diluents.
The solution was then filtered through 0.45µ membrane filter.
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Procedure
              20 µ l of standard solutions were injected and chromatograms were recorded 
and they are shown in fig 123-128 and system suitability reports are given table 22
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RESULTS AND DISCUSSION
The developed method is a simple method which has the advantage of determination
of Tolterodine tartrate with simple solvent system. The analysis time is 12.994mins.
This provides shorter analysis time and conserves the solvent system.
FIXED CHROMATOGRAPHIC CONDITIONS
Instrument                      : AGILENT LC-2011
Column                           : C18
Wavelength                     : 302nm
Flow rate                         : 1ml/min
Injection                          : 20µl
Mobile Phase                  :  Disodium hydrogen Phosphate Buffer : ACN  (73:27) pH   
                                           maintained at 7.6 with phosphoric acid                                
Retention time                 : 12.994 mins
Table:23 QUANTIATIVE ESTIMATION
The method was validated based on USP and ICH parameters:
Parameters validated for the developed method include accuracy, linearity, precision,
interference studies, detection limit, quantitation limit, stability.
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Sl.No Content Standard Peak Area
Sample
Peak Area
Amount
present(mg)
Percentage
content(%)
1 Tolterodine
tartrate
30600.4623 30586.1649 0.9995 99.95
Specificity of the method was found out through non-interference of the placebo in
identical conditions of assay. This confirms the specificity of the developed method.
Linearity  of  the  drug  was  obtained  in  the  range  of  10-100µg/ml.   The  linearity
coefficient and percentage curve fitting slope was found to be 0.999 and 99.9%. 
 Detection limit was done by calibration curve method.The limit of detection was
found to be 0.0002241. Quantitation limit was done by calibration curve method. The
limit of quantification was found to be 0.0006792. 
Accuracy  of  the  method  was  determined  through  recovery  studies  of  the  drug.
Recovery of the drug is well within acceptance limits (98 to 102%). Precision of the
method was determined by assays  of drug formulations by replicate  injection and
precision of system was determined by using standard solution.  %RSD of the assays
is found to be within the limits of 2%. Thus the developed method is found to provide
high degree of precision and reproducibility.
Ruggedness was determined by performing the same assay on different days, assay
being carried out by different analysts. The test results were within the limits 98 to
102%.  The result is found to be reproducible. 
Robustness was determined by carrying out the assay during which the mobile phase
ratio and flow rate was altered. Percent recovery was found to be within 98- 101%,
which is well within the acceptable limits. The low values of RSD obtained with the
change in mobile phase ratio makes it possible to carry out the method with small
variations in the ratio of the mobile phase and flow rate. This indicates the lack of
influence on test results by operational and environmental variables for the developed
method. 
Stability of the method was determined by assays of the drug formulation up to 24hrs
hours. There was almost no appreciable change in absorbance up to 24hrs. Percentage
recovery of the assays was found to be within limits. Thus the developed method was
found to provide high degree of stability
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System suitability was determined by performing the assay with the same sample
repeatedly.  The number of theoretical plates was found to be 4968.The tailing factor
was found to be 1.2. It indicates good and complete separation of the two components
from each other with well defined base line.
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                                         CONCLUSION
The developed chromatographic method for the determination of test procedure of assay
for Tolterodine tartrate in pharmaceutical dosage forms were simple, reliable, sensitive
and less time consuming. The advantage of the present test procedures was that it does
not require any complicated mobile phase and it is simple isocratic method. The present
method can be confidently used for rapid and precise quantitation of  Tolterodine tartrate.
This procedure can be a major interest in analytical pharmacy, since it offers a distinct
quality control in the test procedure of assay of pharmaceutical dosage forms. However
taking into account of the factors such as economy and rapidity, the present method can
also be a good choice for the analysis of Tolterodine tartrate. The developed method may
be recommended for routine and quality control analysis of the investigated drug.
The  present  work  shows,  a  validated,  highly  sensitive  and  selected  method  for  the
determination  of  Tolterodine  tartrate  in  pharmaceutical  dosage  forms.  Precision  and
accuracy as major control parameters of the whole validation procedure was within the
acceptable  limits.  The  experimental  data  makes  a  relevant  contribution  to  the
understanding of validation parameters.
Overall  the  above  developed  analytical  method  represents  a  valuable  data  for  the
validation of Tolterodine tartrate  tablets and rapid quantitation method for the same in
the pharmaceutical dosage forms.
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                                            Table :1 Quantitative Estimation
Sl.No Content StandardPeak Area
Sample
Peak Area
Amount
present(mg)
Percentage
content (%)
1
Tolterodine
tartrate
1mg
30600.4623 30586.1649 0.9995 99.95
                                                 Table :2  Linearity Data
Sl.No Concentration (%) Concentration(µg/ml) Peak Area
1 10 2 6120.0205
2 20 4 12240.1298
3 30 6 18360.4282
4 40 8 24480.1923
5 50 10 30600.1028
6 60 12 36720.2923
7 70 14 42840.2968
8 80 16 48960.3640
                 9 90 18 55080.2343
               10 100 20 61200.3421
                               Table:3  Analytical Performance Parameters
Sl.No Drug LinearityRange
Correlation
Coefficient
Percentage
Curve Fitting
(%)
Slope
1 Tolterodinetartrate 1mg 10-100 0.999 99.99 6120
                                                  Table:4  System Precision data
Sl.No Area of Tolterodine
1 30601.8416
2 30600.5142
3 30601.0012
4 30599.1643
5 30600.1942
6 30601.2398
MEAN 30600.6592
S.D 0.92995
%RSD 0.00303
                                       Table:5  Method Precision Data
Sl.No Area Obtained Amount Present inTablet ( gm)
Percentage content
(%)
1 30584.1965 0.00099946 99.95
2 30586.2198 0.00099942 99.94
3 30586.8129 0.00099944 99.94
4         30585.7689 0.000999447 99.94
5 30584.2925 0.000999365 99.94
6 30586.4415 0.000999435 99.94
MEAN
STANDARD DEVIATION
%RSD
99.942
0.00408
0.00408
                                               Table:6 Specificity for Tolterodine
Sl.No Sample Area Obtained
1 Placebo 0
2 Standard 30600.4623
3 Standard + Placebo 30601.3146
                               Table no:7 Recovery study of Tolterodine
S.No
SAMPLE  -
ID
Amount
added (mg) Area obtained
Amount
found (mg)
Percentage
Recovery(%)
1. 80%
8 24480.1874 7.991 99.89
8 24481.0210 7.992        99.90
8 24479.9862        7.991 99.89
2. 100%
10 30600.2342 9.989 99.89
10 30600.0102 9.989 99.89
10 30599.8929 9.989 99.89
3. 120% 12 36720.2810 11.987 99.89
12 36721.7829 11.988 99.90
12 36719.9928 11.987 99.89
Mean                                                                            
Standard Deviation
% R.S.D
99.89
0.00192
0.001922
RUGGEDNESS
Table:8 Analyst 1
S.No
Date of
Analysis
Standard
Area Sample area
Assay Value
in (gm)
Percentage
content(%)
1 28.10.12 30595.6978 30588.1789 0.00099965 99.97
2 29.10.12 30599.2875 30587.9876 0.00099953 99.95
MEAN
STANDARD DEVIATION
% RELATIVE STANDARD DEVIATION
99.96
0.01414
0.01414
Table:9 Analyst 2
S.No Date of Standard Sample area Assay Value Percentage
Analysis Area in (gm) content(%)
1 28.10.12 30600.4253 30587.2349 0.00099947 99.95
2 29.10.12 30598.2395 30586.7279 0.00099952 99.95
MEAN
STANDARD DEVIATION
% RELATIVE STANDARD DEVIATION
99.95
0.01414
0.01414
Table:10  Instrument variation
S.No Instrument Standard Area Sample Area Assay Value
in (gm)
Percentage 
content(%)
1 INSTRUMENT I 30599.6787 30586.4575 0.000999468 99.95
30597.2686 30588.2939 0.000999607 99.96
30596.3525 30584.3292 0.000999507 99.95
2 INSTRUMENT 
II
30597.9982 30581.9982 0.000999377                          99.94
30598.2212 30586.2343 0.000999508                          99.95
30599.6525 30587.9324 0.000999517                          99.95
MEAN
STANDARD DEVIATION
% RELATIVE STANDARD DEVIATION
99.95 99.95
0.00577 0.00577
0.00577 0.00577
                                                         Table:11
CHROMATOGRAPHIC CONDITION : CHANGE IN MOBILE PHASE RATIO
BUFFER :ACN(74:26)
Flow rate 1.0 ml/min
Instrument LC-2011 
Column C18
Wavelength 302nm
Injection volume 20µl
Mobile phase BUFFER :ACN(74:26)
Table:12 Change In Mobile Phase Ratio
Sl.No Drug Average
standard area
Average sample
area
Percentage
content (%)
1 Tolterodine tartrate 30605.1663 30586.9790 99.93
Table:13
CHROMATOGRAPHIC CONDITION : CHANGE IN MOBILE PHASE RATIO
BUFFER :ACN(72:28)
Flow rate 1.0ml/min
Instrument LC-2011 
Column C18
Wavelength 302nm
Injection volume 20µl
Mobile phase BUFFER :ACN(72:28)
Table :14  Change in mobile phase ratio
Sl.No Drug Average
standard area
Average sample
area
Percentage
content (%)
1 Tolterodine tartrate 30595.1273 30581.8952 99.95
                                                                                    Table:15
CHROMATOGRAPHIC CONDITION : CHANGE IN FLOW RATE  1.1ml/min
Change in flow rate 1.1ml/min
Instrument LC-2011 
Column C18
Wavelength 302nm
Injection volume 20µl
Mobile phase BUFFER :ACN(73:27)
Table:16 Change In Flow Rate  1.1ml/min
Sl.No Drug Average
standard area
Average sample
area
Percentage
content(%)
1 Tolterodine tartrate 30607.0954 30587.7695 99.93
Table:17
CHROMATOGRAPHIC CONDITION : CHANGE IN FLOW RATE  0.9ml/min
Change in flow rate 0.9ml/min
Instrument LC-2011 
Column C18
Wavelength 302nm
Injection volume 20µl
Mobile phase BUFFER :ACN(73:27)
Table:18  Change In Flow Rate  0.9ml/min
Sl.No Drug Average
standard area
Average sample
area
Percentage
content(%)
1 Tolterodine tartrate 30594.7321 30582.6472 99.95
Table:19 Stability Data
Sl.No TimeIntervals(Hours)
Peak area
of blank
Peak area
of placebo
Peak area of
Standard
Peak area of
Sample
1 0 0 0 30600.2343 30585.2214
2 1 0 0 30600.2404 30586.9826
3 2 0 0 30600.6238 30586.6263
4 3 0 0 30600.9219 30584.9989
5 4 0 0 30601.0201 30585.0230
6 5 0 0 30600.4238 30586.0982
7 6 0 0 30599.9826 30585.2218
8 7 0 0 30599.6823 30585.0023
9 8 0 0 30600.0981 30586.7826
10 9 0 0 30599.8623 30586.2302
11 10 0 0 30600.3324 30586.9202
12 12 0 0 30599.5436 30586.9298
13 14 0 0 30599.1829 30585.8223
14 16 0 0 30600.1020 30586.0813
15 18 0 0 30600.0023 30585.0009
16 20 0 0 30599.2864 30586.2292
17 24 0 0 30600.3324 30586.9202
MEAN 30600.1100 30586.0054
STANDARD DEVIATION 0.50696 0.78435
% RSD 0.00165 0.00256
                       Table:22  SYSTEM SUITABILITY PARAMETERS
Parameters Results
Tailing Factor 1.2
Theoretical Plates 4968
%RSD peaks 0.00136
Table:20  Limit Of Detection
Sl.No Area of Tolterodine tartrate
1 30600.4620
2 30600.0021
3 30600.2212
4 30599.2235
5 30599.9829
6 30600.0123
MEAN 30599.984
S.D 0.4157
%RSD 0.00136
                                                      S
3.3LOD σ=
                                    = 0.0002241
           
                                                                  
Table:21 Limit Of Quantitation
Sl.No Area of Tolterodine tartrate
1 30600.4620
2 30600.0021
3 30600.2212
4 30599.2235
5 30599.9829
6 30600.0123
MEAN 30599.984
S.D 0.4157
%RSD 0.00136
               
S
10LOQ σ=
                                     = 0.0006792
                                  Table:24  VALIDATION PARAMETERS
Sl.No Parameters Results Acceptance
Criteria
1 Specificity Complies Complies
2 Correlation Coefficient 0.999 0.99
3 Accuracy 99.89 98-102%
4 Precision
System precision 0.00303 RSD NMT 2.0%
Method precision 0.00408 RSD NMT 2.0%
5 Ruggedness
Analyst I
Analyst II
Instrument I
Instrument II
0.01414
0.01414
0.00577
0.00577
RSD NMT 2.0%
6 Robustness
a)Change in mobile phase ratio
 Buffer :ACN(74:26)
 Buffer :ACN(75:25)
99.93
99.95
98-102%
b)Change in flow rate
0.9ml/min
1.1ml/min 
99.93
99.95
98-102%
7 LOD 0.0002241 -
8 LOQ 0.0006792 -
9 Solution stability
a)Standard response
b)Sample response
0.00165
0.00256
RSD NMT 2.0%
RSD NMT 2.0%
10 System suitability
a)Tailing Factor
b)Theoretical plates 
c)%RSD Peaks
1.2
4968
0.00136
NMT 2
NLT2000
RSD NMT 2.0%
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